1
|
Vellas C, Nayrac M, Collercandy N, Requena M, Jeanne N, Latour J, Dimeglio C, Cazabat M, Barange K, Alric L, Carrere N, Martin-Blondel G, Izopet J, Delobel P. Intact proviruses are enriched in the colon and associated with PD-1 +TIGIT - mucosal CD4 + T cells of people with HIV-1 on antiretroviral therapy. EBioMedicine 2024; 100:104954. [PMID: 38160480 PMCID: PMC10792747 DOI: 10.1016/j.ebiom.2023.104954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Revised: 12/17/2023] [Accepted: 12/19/2023] [Indexed: 01/03/2024] Open
Abstract
BACKGROUND The persistence of intact replication-competent HIV-1 proviruses is responsible for the virological rebound off treatment. The gut could be a major reservoir of HIV-1 due to the high number of infected target cells. METHODS We collected blood samples and intestinal biopsies (duodenum, ileum, colon) from 42 people with HIV-1 receiving effective antiretroviral therapy. We used the Intact Proviral DNA Assay to estimate the frequency of intact HIV-1 proviruses in the blood and in the intestinal mucosa of these individuals. We analyzed the genetic complexity of the HIV-1 reservoir by performing single-molecule next-generation sequencing of HIV-1 env DNA. The activation/exhaustion profile of mucosal T lymphocytes was assessed by flow cytometry. FINDINGS Intact proviruses are particularly enriched in the colon. Residual HIV-1 transcription in the gut is associated with persistent mucosal and systemic immune activation. The HIV-1 intestinal reservoir appears to be shaped by the proliferation of provirus-hosting cells. The genetic complexity of the viral reservoir in the colon is positively associated with TIGIT expression but negatively with PD-1, and inversely related to its intact content. The size of the intact reservoir in the colon is associated with PD-1+TIGIT- mucosal CD4+ T cells, particularly in CD27+ memory cells, whose proliferation and survival could contribute to the enrichment of the viral reservoir by intact proviruses. INTERPRETATION Enrichment in intact proviruses makes the gut a key compartment for HIV-1 persistence on antiretroviral therapy. FUNDING This project was supported by grants from the ANRS-MIE (ANRS EP61 GALT), Sidaction, and the Institut Universitaire de France.
Collapse
Affiliation(s)
- Camille Vellas
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse F-31300, France
| | - Manon Nayrac
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse F-31300, France
| | - Nived Collercandy
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse F-31300, France; CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, Toulouse F-31300, France
| | - Mary Requena
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse F-31300, France; CHU de Toulouse, Laboratoire de Virologie, Toulouse F-31300, France
| | - Nicolas Jeanne
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse F-31300, France; CHU de Toulouse, Laboratoire de Virologie, Toulouse F-31300, France
| | - Justine Latour
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse F-31300, France; CHU de Toulouse, Laboratoire de Virologie, Toulouse F-31300, France
| | - Chloé Dimeglio
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse F-31300, France
| | - Michelle Cazabat
- CHU de Toulouse, Laboratoire de Virologie, Toulouse F-31300, France
| | - Karl Barange
- CHU de Toulouse, Service d'Hépato-Gastro-Entérologie, Toulouse F-31400, France
| | - Laurent Alric
- Université Toulouse III Paul Sabatier, Toulouse F-31400, France; CHU de Toulouse, Service de Médecine Interne et Immunologie clinique, Toulouse F-31400, France
| | - Nicolas Carrere
- Université Toulouse III Paul Sabatier, Toulouse F-31400, France; CHU de Toulouse, Service de Chirurgie Générale et Digestive, Toulouse F-31400, France
| | - Guillaume Martin-Blondel
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse F-31300, France; CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, Toulouse F-31300, France; Université Toulouse III Paul Sabatier, Toulouse F-31400, France
| | - Jacques Izopet
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse F-31300, France; CHU de Toulouse, Laboratoire de Virologie, Toulouse F-31300, France; Université Toulouse III Paul Sabatier, Toulouse F-31400, France
| | - Pierre Delobel
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse F-31300, France; CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, Toulouse F-31300, France; Université Toulouse III Paul Sabatier, Toulouse F-31400, France.
| |
Collapse
|
2
|
Vellas C, Dimeglio C, Joncour E, Staes L, Jamme T, Miedougé M, Da-Silva I, Porcheron M, Migueres M, Kamar N, Izopet J. Evaluation of two anti-SARS-CoV-2 antibody immunoassays for monitoring patients on pre-exposure prophylaxis. Diagn Microbiol Infect Dis 2023; 107:116071. [PMID: 37716217 DOI: 10.1016/j.diagmicrobio.2023.116071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 07/31/2023] [Accepted: 08/22/2023] [Indexed: 09/18/2023]
Abstract
Pre-exposure prophylaxis (PrEP) is crucial to prevent severe COVID-19 in immunocompromised patients. A reliable method is needed to quantify anti-SARS-CoV-2 antibody levels for personalized monitoring during PrEP. We measured the binding antibody concentrations of 63 immunocompromised patients receiving 300mg or 600mg tixagevimab/cilgavimab on PrEP day and twice during the following 3 months. All blood samples were tested using the Abbott anti-SARS-CoV-2 IgG II Quant assay, the Roche Elecsys anti-SARS-CoV-2 S assay, and live virus-based neutralization assays. The results of the two immunoassays were correlated on day 0, 1 month, and 3 months post-PrEP. Passing-Bablok regression demonstrated higher anti-S concentration values measured with the Roche immunoassay compared to those measured with the Abbott immunoassay. Antibody concentrations were higher after 600 mg tixagevimab/cilgavimab prophylaxis than after 300 mg. The neutralizing antibody titers obtained using the omicron BA.5 and BA.2.75 strains were low. Both automated immunoassays are suitable for monitoring immunocompromised patients on PrEP.
Collapse
Affiliation(s)
- Camille Vellas
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France.
| | - Chloé Dimeglio
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France; CHU de Toulouse, Laboratoire de Virologie, Toulouse, France
| | - Emma Joncour
- CHU de Toulouse, Laboratoire de Virologie, Toulouse, France
| | - Laetitia Staes
- CHU de Toulouse, Laboratoire de Virologie, Toulouse, France
| | - Thibaut Jamme
- CHU de Toulouse, Laboratorie de Biochimie, Toulouse, France
| | | | | | | | - Marion Migueres
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France; CHU de Toulouse, Laboratoire de Virologie, Toulouse, France
| | - Nassim Kamar
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France; CHU de Toulouse, Département de Néphrologie, Dialyse et Transplantation d'Organes, Toulouse, France
| | - Jacques Izopet
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France; CHU de Toulouse, Laboratoire de Virologie, Toulouse, France
| |
Collapse
|
3
|
Vellas C, Latour J, Trémeaux P, Ranger N, Ferrer V, Harter A, Carcenac R, Boyer P, Demmou S, Claraz P, Kamar N, Izopet J. Molecular evolution of omicron variant in immunocompromised individuals with chronic SARS-CoV-2 infection. J Infect 2023; 87:e89-e93. [PMID: 37783375 DOI: 10.1016/j.jinf.2023.09.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Accepted: 09/28/2023] [Indexed: 10/04/2023]
Affiliation(s)
- Camille Vellas
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III (University of Toulouse III), Toulouse Institute for Infectious and Inflammatory Diseases, F-31300, France; Université Toulouse III Paul Sabatier, F-31300, France.
| | - Justine Latour
- CHU de Toulouse (Toulouse University Hospital), Laboratoire de Virologie (Virology Laboratory), Toulouse F-31300, France
| | - Pauline Trémeaux
- CHU de Toulouse (Toulouse University Hospital), Laboratoire de Virologie (Virology Laboratory), Toulouse F-31300, France
| | - Noémie Ranger
- CHU de Toulouse (Toulouse University Hospital), Laboratoire de Virologie (Virology Laboratory), Toulouse F-31300, France
| | - Vénicia Ferrer
- CHU de Toulouse (Toulouse University Hospital), Laboratoire de Virologie (Virology Laboratory), Toulouse F-31300, France
| | - Agnès Harter
- CHU de Toulouse (Toulouse University Hospital), Laboratoire de Virologie (Virology Laboratory), Toulouse F-31300, France
| | - Romain Carcenac
- CHU de Toulouse (Toulouse University Hospital), Laboratoire de Virologie (Virology Laboratory), Toulouse F-31300, France
| | - Pauline Boyer
- CHU de Toulouse (Toulouse University Hospital), Laboratoire de Virologie (Virology Laboratory), Toulouse F-31300, France
| | - Sofia Demmou
- CHU de Toulouse (Toulouse University Hospital), Laboratoire de Virologie (Virology Laboratory), Toulouse F-31300, France
| | - Pauline Claraz
- Institut Universitaire du Cancer (University Cancer Institute), Service de Pharmacie (Pharmacy Department), Toulouse F-31100, France
| | - Nassim Kamar
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III (University of Toulouse III), Toulouse Institute for Infectious and Inflammatory Diseases, F-31300, France; Université Toulouse III Paul Sabatier, F-31300, France; CHU de Toulouse, Département de Néphrologie, Dialyse et Transplantation d'Organes (Department of Nephrology, Dialysis and Organ Transplantation), Toulouse F-31400, France
| | - Jacques Izopet
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III (University of Toulouse III), Toulouse Institute for Infectious and Inflammatory Diseases, F-31300, France; Université Toulouse III Paul Sabatier, F-31300, France; CHU de Toulouse (Toulouse University Hospital), Laboratoire de Virologie (Virology Laboratory), Toulouse F-31300, France
| |
Collapse
|
4
|
Vellas C, Kamar N, Izopet J. Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment. J Infect 2022; 85:e162-e163. [PMID: 35878684 PMCID: PMC9307285 DOI: 10.1016/j.jinf.2022.07.014] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2022] [Accepted: 07/16/2022] [Indexed: 02/04/2023]
Affiliation(s)
- Camille Vellas
- INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse F-31300, France; Toulouse University Hospital, Virology Laboratory, Toulouse F-31300, France; Université Toulouse III Paul Sabatier, Toulouse F-31300, France.
| | - Nassim Kamar
- INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse F-31300, France; Université Toulouse III Paul Sabatier, Toulouse F-31300, France; Toulouse University Hospital, Department of Nephrology, Dialysis, and Multi-Organ Transplantation, Toulouse, F-31300 France
| | - Jacques Izopet
- INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse F-31300, France; Toulouse University Hospital, Virology Laboratory, Toulouse F-31300, France; Université Toulouse III Paul Sabatier, Toulouse F-31300, France.
| |
Collapse
|
5
|
Vellas C, Del Bello A, Gaube G, Tremeaux P, Jeanne N, Ranger N, Martin-Blondel G, Delobel P, Kamar N, Izopet J. Impact of Casirivimab-Imdevimab on SARS-CoV-2 delta variant nasopharyngeal virus load and Spike quasispecies. Open Forum Infect Dis 2022; 9:ofac093. [PMID: 35299988 PMCID: PMC8903465 DOI: 10.1093/ofid/ofac093] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Accepted: 02/20/2022] [Indexed: 11/16/2022] Open
Abstract
Background The increasing use of monoclonal antibodies (mAbs) to treat coronavirus disease 2019 raises questions about their impact on the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mAb-resistant variants. We assessed the impact of Casirivimab-Imdevimab on SARS-CoV-2 mutations associated with reduced mAb activity in treated patients. Methods We measured the nasopharyngeal (NP) viral load and sequenced the haplotypes of spike gene of 50 patients infected with the SARS-CoV-2 delta variant and treated with Casirivimab-Imdevimab using single-molecule real-time sequencing. Results The NP SARS-CoV-2 viral load of patients treated with Casirivimab-Imdevimab decreased from 8.13 (interquartile range [IQR], 7.06–8.59) log10 copies/mL pretreatment to 3.67 (IQR, 3.07–5.15) log10 copies/mL 7 days later (P < .001). Of the 36 patients for whom follow-up timepoints Spike sequencing were available, none of the Spike mutations that reduced mAb activity were detected. Conclusions Casirivimab-Imdevimab is an effective treatment for patients infected with the SARS-CoV-2 delta variant. Despite selective pressure on SARS-CoV-2 Spike quasispecies, we detected no key mutations that reduced mAb activity in our patients.
Collapse
Affiliation(s)
- Camille Vellas
- CHU de Toulouse, Laboratoire de Virologie, Toulouse, F-31300 France
- INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, F-31300 France
- Université Toulouse III Paul Sabatier, Toulouse, F-31300 France
| | - Arnaud Del Bello
- INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, F-31300 France
- Université Toulouse III Paul Sabatier, Toulouse, F-31300 France
- CHU de Toulouse, Département de Néphrologie, Dialyse et Transplantation d'Organes, Toulouse, F-31300 France
| | - Géraldine Gaube
- CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, Toulouse, F-31300 France
| | - Pauline Tremeaux
- CHU de Toulouse, Laboratoire de Virologie, Toulouse, F-31300 France
| | - Nicolas Jeanne
- CHU de Toulouse, Laboratoire de Virologie, Toulouse, F-31300 France
| | - Noémie Ranger
- CHU de Toulouse, Laboratoire de Virologie, Toulouse, F-31300 France
| | - Guillaume Martin-Blondel
- INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, F-31300 France
- Université Toulouse III Paul Sabatier, Toulouse, F-31300 France
- CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, Toulouse, F-31300 France
| | - Pierre Delobel
- INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, F-31300 France
- Université Toulouse III Paul Sabatier, Toulouse, F-31300 France
- CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, Toulouse, F-31300 France
| | - Nassim Kamar
- INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, F-31300 France
- Université Toulouse III Paul Sabatier, Toulouse, F-31300 France
- CHU de Toulouse, Département de Néphrologie, Dialyse et Transplantation d'Organes, Toulouse, F-31300 France
| | - Jacques Izopet
- CHU de Toulouse, Laboratoire de Virologie, Toulouse, F-31300 France
- INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, F-31300 France
- Université Toulouse III Paul Sabatier, Toulouse, F-31300 France
| |
Collapse
|
6
|
Del Bello A, Marion O, Vellas C, Faguer S, Izopet J, Kamar N. Anti-SARS-CoV-2 Monoclonal Antibodies in Solid-organ Transplant Patients. Transplantation 2021; 105:e146-e147. [PMID: 34224543 PMCID: PMC8487703 DOI: 10.1097/tp.0000000000003883] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Revised: 06/02/2021] [Accepted: 06/20/2021] [Indexed: 11/30/2022]
Affiliation(s)
- Arnaud Del Bello
- Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, Toulouse, France
- INFINITY- Inserm U1291-CNRS U5051, Toulouse, France
| | - Olivier Marion
- Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, Toulouse, France
- INFINITY- Inserm U1291-CNRS U5051, Toulouse, France
- Paul Sabatier University, Toulouse, France
| | - Camille Vellas
- Laboratory of Virology, Toulouse Purpan University Hospital, INSERM, Toulouse, France
| | - Stanislas Faguer
- Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, Toulouse, France
- Paul Sabatier University, Toulouse, France
| | - Jacques Izopet
- INFINITY- Inserm U1291-CNRS U5051, Toulouse, France
- Paul Sabatier University, Toulouse, France
- Laboratory of Virology, Toulouse Purpan University Hospital, INSERM, Toulouse, France
| | - Nassim Kamar
- Department of Nephrology and Organ Transplantation, Toulouse Rangueil University Hospital, Toulouse, France
- INFINITY- Inserm U1291-CNRS U5051, Toulouse, France
- Paul Sabatier University, Toulouse, France
| |
Collapse
|
7
|
Vellas C, Del Bello A, Debard A, Steinmeyer Z, Tribaudeau L, Ranger N, Jeanne N, Martin-Blondel G, Delobel P, Kamar N, Izopet J. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies. Clin Microbiol Infect 2021; 28:139.e5-139.e8. [PMID: 34537363 PMCID: PMC8444376 DOI: 10.1016/j.cmi.2021.09.008] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2021] [Revised: 08/30/2021] [Accepted: 09/08/2021] [Indexed: 01/01/2023]
Abstract
Objectives To evaluate the impact of neutralizing monoclonal antibody (mAb) treatment and to determine whether the selective pressure of mAbs could facilitate the proliferation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with spike protein mutations that might attenuate mAb effectiveness. Patients and methods We evaluated the impact of mAbs on the nasopharyngeal (NP) viral load and virus quasispecies of mAb-treated patients using single-molecule real-time sequencing. The mAbs used were: Bamlanivimab alone (four patients), Bamlanivimab/Etesevimab (23 patients) and Casirivimab/Imdevimab (five patients). Results The NP SARS-CoV-2 viral load of mAb-treated patients decreased from 8.2 log10 copies/mL before administration to 4.3 log10 copies/mL 7 days after administration. Five immunocompromised patients given Bamlanivimab/Etesevimab were found to have mAb activity-reducing spike mutations. Two patients harboured SARS-CoV-2 variants with a Q493R spike mutation 7 days after administration, as did a third patient 14 days after administration. The fourth patient harboured a variant with a Q493K spike mutation 7 days post-treatment, and the fifth patient had a variant with a E484K spike mutation on day 21. The emergence of the spike mutation was accompanied by stabilization or rebound of the NP viral load in three of five patients. Conclusion Two-mAb therapy can drive the selection of resistant SARS-CoV-2 variants in immunocompromised patients. Patients given mAbs should be closely monitored and measures to limit virus spread should be reinforced.
Collapse
Affiliation(s)
- Camille Vellas
- CHU de Toulouse, Virology Laboratory, Toulouse, France; INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France.
| | - Arnaud Del Bello
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France; CHU de Toulouse, Département de Néphrologie, Dialyse et Transplantation d'Organes, Toulouse, France
| | - Alexa Debard
- CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, Toulouse, France
| | | | - Laure Tribaudeau
- Université Toulouse III Paul Sabatier, Toulouse, France; CHU de Toulouse, C.O.M.E.D.I.M.S, Toulouse, France
| | - Noémie Ranger
- CHU de Toulouse, Virology Laboratory, Toulouse, France
| | | | - Guillaume Martin-Blondel
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France; CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, Toulouse, France
| | - Pierre Delobel
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France; CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, Toulouse, France
| | - Nassim Kamar
- INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France; CHU de Toulouse, Département de Néphrologie, Dialyse et Transplantation d'Organes, Toulouse, France
| | - Jacques Izopet
- CHU de Toulouse, Virology Laboratory, Toulouse, France; INSERM UMR1291-CNRS UMR5051-Université Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France
| |
Collapse
|
8
|
Migueres M, Vellas C, Abravanel F, Da Silva I, Dimeglio C, Ferrer V, Raymond S, Mansuy JM, Izopet J. Testing individual and pooled saliva samples for sars-cov-2 nucleic acid: a prospective study. Diagn Microbiol Infect Dis 2021; 101:115478. [PMID: 34364098 PMCID: PMC8279932 DOI: 10.1016/j.diagmicrobio.2021.115478] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 06/24/2021] [Accepted: 06/28/2021] [Indexed: 12/23/2022]
Abstract
Control of the rapid spread of the SARS-CoV-2 virus requires efficient testing. We collected paired nasopharyngeal swab (NPs) and saliva samples from 303 subjects (52.8% symptomatic) at a drive-through testing center; 18% of whom tested positive. The NPs, salivas and five saliva pools were tested for SARS-CoV-2 RNA using the Aptima™ assay and a laboratory-developed test (LDT) on the Panther-Fusion™ Hologic® platform. The saliva sensitivity was 80% (LDT) and 87.5% (Aptima™) whereas that of NPs was 96.4% in both assays. The pooled saliva sensitivity of 72.7% (LDT) and 75% (Aptima™) was not significantly different of that of individual saliva testing. Saliva specimens appear to be suitable for sensitive non-invasive assays to detect SARS-CoV-2 nucleic acid; pooling them for a single test will improve laboratory throughput.
Collapse
Affiliation(s)
- Marion Migueres
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse, France; Department of Virology, Université Toulouse III Paul-Sabatier, Toulouse, France.
| | - Camille Vellas
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse, France; Department of Virology, Université Toulouse III Paul-Sabatier, Toulouse, France
| | - Florence Abravanel
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse, France; Department of Virology, Université Toulouse III Paul-Sabatier, Toulouse, France
| | | | - Chloé Dimeglio
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, France
| | - Venicia Ferrer
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, France
| | - Stéphanie Raymond
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse, France; Department of Virology, Université Toulouse III Paul-Sabatier, Toulouse, France
| | | | - Jacques Izopet
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse, France; Department of Virology, Université Toulouse III Paul-Sabatier, Toulouse, France
| |
Collapse
|
9
|
Abstract
A new coronavirus, called SARS-CoV-2, was identified in Wuhan, China, in December 2019. The SARS-CoV-2 spread very rapidly, causing a global pandemic, Coronavirus Disease 2019 (COVID-19). Older adults have higher peak of viral load and, especially those with comorbidities, had higher COVID-19-related fatality rates than younger adults. In this Perspective paper, we summarize current knowledge about SARS-CoV-2 and aging, in order to understand why older people are more affected by COVID-19. We discuss about the possibility that the so-called "immunosenescence" and "inflammaging" processes, already present in a fraction of frail older adults, could allow the immune escape of SARS-CoV-2 leading to COVID-19 serious complications. Finally, we propose to use geroscience approaches to the field of COVID-19.
Collapse
Affiliation(s)
- C Vellas
- Camille Vellas, INSERM UMR1043 - CNRS UMR5282 Centre de Physiopathologie Toulouse-Purpan (CPTP), Toulouse, France,
| | | | | | | |
Collapse
|